Discover mental health
September 17, 2024
S K Spoelstra, R A Schoevers, S D Venema et al.
8 citations
Tobacco use disorder remains a major public health problem, and current cessation therapies have limited effectiveness. This review evaluated scientific evidence on psychedelics for smoking cessation by searching four databases up to March 2024. From 1073 articles, 8 publications met inclusion criteria, with 4 originating from a single study. Most studies focused on psilocybin (7 of 8), for which supportive evidence was suggested for treating tobacco use disorder. Research on ayahuasca, mescaline, peyote, LSD, LSA, and DMT was too limited to draw definitive conclusions. There is limited evidence that psychedelics, particularly psilocybin, may offer a potential avenue for combating tobacco use disorder, though more research is needed.
Clinical psychology review
February 2, 2026
J K E Veraart, N Schimmers, J J Breeksema et al.
4 citations
Ketamine-assisted psychotherapy (KAP) combines psychotherapeutic interventions with the rapid-acting effects of ketamine to treat psychiatric disorders. This systematic review of 64 articles (72 studies) up to 2025 found only 11 were randomized controlled trials (RCTs), highlighting limited evidence. Therapeutic approaches varied, with most classified as 'other.' Results suggest transdiagnostic effectiveness for major depressive disorder, posttraumatic stress disorder, obsessive-compulsive disorder, substance use disorders, and eating disorders. Compared to psychotherapy alone, KAP enhanced treatment engagement, symptom reduction, and duration of response. However, only two studies randomized psychotherapy alongside ketamine, neither reporting added effects; one also randomized ketamine and found no significant interaction. This limited evidence does not support added benefit or synergy from combining psychotherapy with ketamine.